Janus kinase inhibitors such as tofacitinib (JAK1/3 inhibitor), ruxolitinib (JAK1/JAK2 inhibitor), and baricitinib (JAK1/2 inhibitor) were studied in patients with JDM (12–19). Here, JAK1 is linked to juvenile dermatomyositis.